Renal related adverse events (Figure 10)
The following outcomes were studied for renal-related adverse events: acute kidney injury, hospitalization due to acute kidney injury, discontinuation of trial regimen due to acute kidney injury and hospitalization due to acute renal failure. Four out of seven studies[5,10,14,15] reported acute kidney injury, and the pooled analysis revealed that treatment with Finerenone was associated with a slightly lower risk of acute kidney injury (RR = 0.94 [0.84, 1.05] p= 0.30, I2= 0%) whereas hospitalization due to acute kidney injury, discontinuation of treatment regimen due to acute kidney injury and hospitalization due to acute renal failure was reported by three out of seven studies [5,10,14] and the pooled analysis revealed that the risk of hospitalization due to acute kidney injury and risk of hospitalization due to acute renal failure was similar in both treatment groups, (RR = 0.99 [0.80, 1.22] p=0.91; I2= 0%) and (RR = 0.97 [0.80, 1,18] p= 0.76; I2= 0%) respectively, whereas the risk of discontinuation of treatment regimen due to acute kidney injury was higher in Finerenone group (RR = 1.38 [0.69, 2.75] p = 0. 37; I2= 0%)